Complying With the DSCSA
Dave DeJean provides his expert insight on lessons he’s learned from his plethora of time in the industry, along with an outlook on where the pharma supply chain stands in adhering to the Drug Supply Chain Security Act (DSCSA).
In this exclusive PC Podcast interview, Dave DeJean, Systech’s VP of global strategic accounts, dives into:
- The valuable lessons he’s learned along the way, given his three and half decades of experience at Systech
- An overview of the Drug Supply Chain Security Act (DSCSA), including its three main pillars
- How he would interpret this “Stabilization Period” that the FDA provided this past summer, and what he pharma industry do now during this period in order to avoid penalties later
- Whether or not he anticipates the FDA implementing any other sort of delays in the near future in order to help remedy these issues/challenges surrounding the enactment of DSCSA
The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.
Recent Videos
Related Content
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024Article
In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
